London, 10 October 2008 - EastPharma (EAST LI), a company active in
the manufacturing and marketing of branded generic and in-licensed
pharmaceutical products in Turkey and selected emerging markets,
announces today that the Board of Directors of Deva Holding has
approved an increase in the capital of Deva Holding from YTL
48,000,000 to YTL 100,000,000. EastPharma will exercise its
pre-emptive rights in full.
The monies raised amounts to YTL 52,000,000, (approximately USD
37.6mn at the exchange rate of October 9). The capital increase is
being carried out to improve Deva Holding's working capital.
For further information, please contact:
EastPharma
Idil Bora - Investor Relations
Tel: + 90 (212) 6929326
---END OF MESSAGE---
